This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Payton, M. Articles by Coats, S. Search for Related Content PubMed PubMed Citation Articles by Payton, M. Articles by Coats, S.

Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors

Departments of ¹ Cancer Biology, ² Molecular Pharmacology, ³ Cancer Pharmacology, and ⁴ Chemistry Research and Development, Amgen, Inc., Thousand Oaks, California

Requests for reprints: Marc Payton, Amgen, Inc., One Amgen Center Drive, Mailstop 5-2A, Thousand Oaks, CA 91320-1789. Phone: 805-447-6697; Fax: 805-375-8368; E-mail: mpayton{at}amgen.com.

In eukaryotic cells, cyclin-dependent kinase (CDK) complexes regulate the temporal progression of cells through the cell cycle. Deregulation in the cell cycle is an essential component in the evolution of cancer. Here, we validate CDK1 and CDK2 as potential therapeutic targets using novel selective small-molecule inhibitors of cyclin B1/CDK1 and cyclin E2/CDK2 enzyme complexes (CDKi). Flow cytometry–based methods were developed to assess intracellular retinoblastoma (Rb) phosphorylation to show inhibition of the CDK pathway. Tumor cells treated with CDK inhibitors showed an overall decrease in cell proliferation, accumulation of cells in G₁ and G₂, and apoptosis in a cell line–specific manner. Although CDK inhibitors activate p53, the inhibitors were equipotent in arresting the cell cycle in isogenic breast and colon tumor cells lacking p53, suggesting the response is independent of p53. In vivo, the CDK inhibitors prevented the growth of colon and prostate tumors, blocked proliferation of tumor cells, and inhibited Rb phosphorylation. The discovery and evaluation of novel potent and selective CDK1 and CDK2 inhibitors will help delineate the role that CDK complexes play in regulating tumorigenesis. (Cancer Res 2006; 66(8): 4299-308)

This article has been cited by other articles:

				C. Zhang, K. Lundgren, Z. Yan, M. E. Arango, S. Price, A. Huber, J. Higgins, G. Troche, J. Skaptason, T. Koudriakova, et al. Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy Mol. Cancer Ther., April 1, 2008; 7(4): 818 - 828. [Abstract] [Full Text] [PDF]

				D. A. Skoufias, R.-L. Indorato, F. Lacroix, A. Panopoulos, and R. L. Margolis Mitosis persists in the absence of Cdk1 activity when proteolysis or protein phosphatase activity is suppressed J. Cell Biol., November 19, 2007; 179(4): 671 - 685. [Abstract] [Full Text] [PDF]

				K. Bettayeb, O. M. Tirado, S. Marionneau-Lambot, Y. Ferandin, O. Lozach, J. C. Morris, S. Mateo-Lozano, P. Drueckes, C. Schachtele, M. H.G. Kubbutat, et al. Meriolins, a New Class of Cell Death Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin-Dependent Kinases Cancer Res., September 1, 2007; 67(17): 8325 - 8334. [Abstract] [Full Text] [PDF]

				L. A. Gomez, A. de las Pozas, T. Reiner, K. Burnstein, and C. Perez-Stable Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy Mol. Cancer Ther., May 1, 2007; 6(5): 1534 - 1543. [Abstract] [Full Text] [PDF]

				D. Cai, V. M. Latham Jr., X. Zhang, and G. I. Shapiro Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res., September 15, 2006; 66(18): 9270 - 9280. [Abstract] [Full Text] [PDF]